TLE3 loss confers AR inhibitor resistance by facilitating GR-mediated human prostate cancer cell growth

Androgen receptor (AR) inhibitors represent the mainstay of prostate cancer treatment. In a genome-wide CRISPR-Cas9 screen using LNCaP prostate cancer cells, loss of co-repressor TLE3 conferred resistance to AR antagonists apalutamide and enzalutamide. Genes differentially expressed upon TLE3 loss s...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:eLife
Main Authors: Palit, Sander AL, Vis, Daniel, Stelloo, Suzan, Lieftink, Cor, Prekovic, Stefan, Bekers, Elise, Hofland, Ingrid, Šuštić, Tonći, Wolters, Liesanne, Beijersbergen, Roderick, Bergman, Andries M, Győrffy, Balázs, Wessels, Lodewyk FA, Zwart, Wilbert, van der Heijden, Michiel S
Formato: Artigo
Idioma:Inglês
Publicado em: eLife Sciences Publications, Ltd 2019
Assuntos:
Cancer Biology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6968917/
https://ncbi.nlm.nih.gov/pubmed/31855178
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7554/eLife.47430
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados